Table of Contents
A diagnostic that took eight years and a fortune to develop can fail at the patent office for a reason that has nothing to do with whether it works. In the life sciences, the hardest question is often not whether your invention is novel, but whether U.S. law will treat it as eligible for a patent at all. Life science patents sit on a fault line that has shifted under researchers since the Supreme Court’s decisions in Mayo, Myriad, and Alice. Get the strategy right and you protect a decade of R&D. Get it wrong and a rival can practice your discovery freely. These six rules are where to start.
Why Life Science Patents Face an Eligibility Problem
The threshold hurdle for life science patents is 35 U.S.C. § 101, which sets out what can be patented and, by judicial exception, what cannot: laws of nature, natural phenomena, and abstract ideas. Three Supreme Court cases reshaped how that exception hits the life sciences.
- Mayo v. Prometheus (2012): a diagnostic correlation between a drug dose and the body’s response was held to be an unpatentable law of nature.
- AMP v. Myriad Genetics (2013): isolated, naturally occurring DNA is not eligible, though synthetic cDNA is.
- Alice v. CLS Bank (2014): set the two-step test now used to judge every exception, including in biotech software and AI-driven tools.
The practical effect is that diagnostics, natural products, and gene-based inventions face scrutiny that a mechanical device never sees. This is the single biggest reason life sciences IP strategy differs from the rest of the patent world, and why claim drafting here is a specialist task, not a template exercise.
Rule 1: Draft Claims Around the Exceptions
Eligibility is won or lost in the claims. The same underlying discovery can be eligible or not depending on how it is framed. After Mayo, a claim that simply recites a natural correlation and says “observe it” fails; a claim directed to a specific, non-routine application, a novel treatment step, a particular composition, an engineered tool, has a far better chance.
- Favor composition-of-matter claims for engineered molecules, vectors, and cell lines.
- Frame diagnostics as specific method-of-treatment steps, not bare correlations.
- Add a concrete, non-conventional technical step that the prior art did not perform routinely.
- Pursue layered claim sets so one rejected claim type does not sink the whole filing.
The strategic point: do not file a single theory of eligibility and hope. Build a portfolio of claim types around the same invention so that if one path closes, another stays open. This is the discipline that separates a granted asset from an abandoned application, and it is covered in depth in our biotech and life sciences patents guide.
Rule 2: Protect the Full Patent Term You Earn
A patent generally runs about 20 years from its earliest filing, but in pharma that clock starts long before a product can be sold. Years of clinical trials and FDA review can consume much of the term before a single dollar of revenue arrives.
U.S. law offers a partial remedy. Under the Hatch-Waxman framework (35 U.S.C. § 156), a patent can qualify for patent term extension to recover part of the time lost to regulatory review, and patent term adjustment separately compensates for certain USPTO delays. These are not automatic; they require timely, correct filings, and missing a deadline can forfeit years of exclusivity. For drug developers, term strategy is as important as the original grant, and it should be mapped at filing, not discovered at launch.
Rule 3: Pair Patents With Trade Secrets
Not everything valuable in the lab belongs in a patent. A patent requires public disclosure, and a patent application publishes, typically eighteen months after filing, teaching the world how to make your invention in exchange for time-limited exclusivity. Some assets are better kept secret.
- Patent: novel compounds, formulations, and methods you can detect being infringed.
- Trade secret: manufacturing processes, cell-culture conditions, and know-how that are hard to reverse-engineer.
- Both, in sequence: file on the product, keep the process confidential behind it.
Trade secrets, protected federally under the Defend Trade Secrets Act, last as long as secrecy holds, with no twenty-year ceiling, but vanish the moment the information leaks or is independently discovered. The decision between the two is one of the most consequential in life sciences IP, and we walk through it in trade secret vs patent. The strongest programs use both deliberately, not by accident.
Rule 4: Plan a Global Filing Strategy Early
Eligibility law is not the same everywhere, and the differences favor planning. The European Patent Office applies its own standards and, in several areas, permits biotech claims, including certain diagnostic and gene-related inventions, that U.S. courts have rejected. The reverse is also true in places. A discovery that struggles under Section 101 may be protectable abroad, and vice versa.
- Decide target markets before the 12-month priority and 30-month PCT national-stage deadlines.
- Tailor claim sets to each jurisdiction’s eligibility rules rather than filing one identical set.
- Coordinate disclosures, since a public presentation can destroy rights in countries without a U.S.-style grace period.
- Budget for translation and prosecution in each region from the start.
The recurring mistake is treating foreign filing as an afterthought once a product gains traction. By then, priority deadlines may have passed and early disclosures may have foreclosed protection. Map the geography while the research is still in the lab.
Rule 5 and 6: Run Diligence and Watch the Law
The last two rules are continuing duties rather than one-time tasks. Rule 5: run real diligence. Before committing R&D dollars or closing a deal, confirm both that you can protect the invention and that you are free to practice it without infringing others. In a field this crowded, a freedom-to-operate gap can be fatal, and a clean one is a selling point. Our overview of IP due diligence shows what a thorough review covers.
Rule 6: watch the law, because it is moving. Congress has repeatedly considered the proposed Patent Eligibility Restoration Act, which would narrow the judicial exceptions and restore protection for many diagnostics and biotech inventions. It has not been enacted as of 2026, so the Mayo–Myriad framework still governs, but a change would reshape strategy overnight. Build a portfolio that is defensible under today’s rules yet flexible enough to benefit if they loosen. You can track the current eligibility standard through the USPTO’s subject matter eligibility guidance.
How PerspireIP Can Help
Protecting life science innovation takes more than filing an application; it takes claim drafting built for Section 101, a term and trade-secret strategy, and a global plan set before deadlines close. Our patent attorneys help biotech, pharma, and diagnostics teams turn research into defensible, durable rights. Contact us to build an IP strategy that protects your R&D from the lab bench to the market.
Frequently Asked Questions
Are life science patents harder to obtain than other patents?
Often, yes, because of Section 101 eligibility. Diagnostics, natural products, and gene-based inventions face scrutiny under the Mayo, Myriad, and Alice decisions that mechanical or many software inventions do not, making careful claim drafting essential.
Can you patent a gene or a naturally occurring molecule?
Not in its natural, isolated form. Under Myriad, naturally occurring DNA is not patent eligible, but synthetic cDNA and engineered molecules can be. Composition claims to non-naturally-occurring constructs are a common path.
How long do life science patents last?
Generally about 20 years from the earliest filing date. Pharmaceutical patents may recover some time lost to FDA review through patent term extension under the Hatch-Waxman framework, which must be applied for correctly and on time.
Should I use a patent or a trade secret?
It depends on detectability and disclosure. Patent inventions you can catch others infringing; keep as trade secrets the processes and know-how that are hard to reverse-engineer. Many life sciences programs use both, patenting the product while protecting the process.
Will the law on patent eligibility change?
It may. The proposed Patent Eligibility Restoration Act would narrow the judicial exceptions, but it has not been enacted as of 2026, so the current Mayo-Myriad-Alice framework still governs. Build a portfolio that works today and can adapt if the law changes.